G9pharma co., LTD reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net income was KRW 133.36 million compared to net loss of KRW 8,200.85 million a year ago. Basic earnings per share from continuing operations was KRW 33 compared to basic loss per share from continuing operations of KRW 2,011 a year ago. Diluted earnings per share from continuing operations was KRW 33 compared to diluted loss per share from continuing operations of KRW 2,011 a year ago. Basic earnings per share was KRW 33 compared to basic loss per share of KRW 2,011 a year ago.
For the six months, net loss was KRW 2,290.64 million compared to KRW 13,322.27 million a year ago. Basic loss per share from continuing operations was KRW 562 compared to KRW 3,266 a year ago. Diluted loss per share from continuing operations was KRW 562 compared to KRW 3,266 a year ago. Basic loss per share was KRW 562 compared to KRW 3,266 a year ago.